Lacosamide Tablet was approved by NMPA_Shijiazhuang No.4 Pharmaceutical

Contact Us

Web Copyright: Shijiazhuang No.4 Pharmaceutical Co., Ltd. Powered by www.300.cn 冀ICP备05007979号-1

Add: No. 288,Zhujiang Road, High-tech Industrial

Development,Shijiazhuang, Hebei, China
Web: www.sjzsiyao.com
Tel: 86 311 67167137 / 67167144
E-mail: trade@sjzsiyao.com / chinainfusion@163.com
Skype: xlmamary

About Us

Online Message

Lacosamide Tablet was approved by NMPA

[Abstract]:

LACOSAMIDE TABLET WAS APPROVED BY NMPA Our company, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has obtained the approval of drug production registration for Lacosamide tablets (50mg and 100mg) from the National Medical Products Administration, which belongs to class 4 new chemical drugs and is regarded as passing the consistency evaluation. Lacosamide can regulate the activity of sodium ion channel, effectively reduce sodium ion influx, reduce the excitability of neurons, and achieve the purpose of treating epilepsy, mainly used for the monotherapy and combination therapy of partial seizures in patients with epilepsy aged 4 years and above.

LACOSAMIDE TABLET WAS APPROVED BY NMPA

Our company, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has obtained the approval of drug production registration for Lacosamide tablets (50mg and 100mg) from the National Medical Products Administration, which belongs to class 4 new chemical drugs and is regarded as passing the consistency evaluation.

Lacosamide can regulate the activity of sodium ion channel, effectively reduce sodium ion influx, reduce the excitability of neurons, and achieve the purpose of treating epilepsy, mainly used for the monotherapy and combination therapy of partial seizures in patients with epilepsy aged 4 years and above.

Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength